James T. Parsons - Jan 3, 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Director
Signature
/s/ Amy Culbert, attorney-in-fact
Stock symbol
DMAC
Transactions as of
Jan 3, 2022
Transactions value $
$60,047
Form type
4
Date filed
1/3/2022, 03:21 PM
Previous filing
Nov 19, 2021
Next filing
Jun 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMAC Voting Common Shares, no par value per share Award $60K +16.8K +77.17% $3.58 38.5K Jan 3, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $60,000.
F2 Amount reflects the cancellation of 211 shares underlying deferred share units granted in lieu of Board committee retainers due to a change in Board committee memberships.
F3 Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 32,409 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan.